Treatment-Resistant Depression Treatment Market is expected to reach US$ 4 Billion by 2033

In 2023, the global Treatment-Resistant Depression Treatment Market is anticipated to be worth US$ 1.69 billion. Because of the rising frequency of depression and anxiety disorders in adults, as well as the ageing population, the global demand for treatment-resistant depression treatment is expected to expand at a CAGR of 9.0% between 2023 and 2033, totaling roughly US$ 4.0 billion by 2033. The increasing prevalence of Treatment-Resistant Depression has raised awareness about its treatment. Several market participants are creating sophisticated medications that can be supplied via nasal and intravenous channels rather than the standard oral route.

Traditional antidepressants used for this disorder may take at least 4-6 weeks to produce an impact, with the danger of partial or unsatisfactory outcomes when administered orally, whereas intranasal has been shown to generate superior benefits within hours of delivery. For example, according to a January 2022 study published in Pharmacopsychiatry, Novartis Pharmaceuticals’ innovative pipeline antidepressant MIJ821 revealed a more significant reduction in depression episodes within 24 hours of dosing through infusion monthly among patients.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15965

Furthermore, the overall results showed that treatment with intranasal esketamine in combination with a novel oral antidepressant was more effective than placebo plus oral delivery. Intranasal esketamine demonstrated a rapid reduction in depression symptoms and delayed relapse time. Additionally, increased research and development for sophisticated pharmaceuticals via alternative modes of administration is expected to boost drug demand, consequently expanding total market growth.

According to the World Health Organization (WHO), the prevalence of mental health diseases and ailments is increasing worldwide. In the recent decade, there has been a 13% increase in mental health issues and other depressive diseases. According to the U.S. Department of Health and Human Services (HHS), in 2020, 17.0% (approximately 4.1 million individuals) of adolescents aged 12 to 17 had a major depressive episode (MDE), and 12% (about 2.9 million people) had an MDE with severe impairment.

Key Takeaways from the Market Study

• Global treatment-resistant depression treatment market was valued at US$ 1.55 Billion by 2022-end
• From 2018 to 2022, the market demand expanded at a CAGR of 3.3%
• By drug type, the NMDA segment of the market constitutes the bulk of the market with a market share of 49%
• By Distribution Channel, the Hospital Pharmacies segment dominates the market with a share of 47%
• From 2023 to 2033, Treatment-Resistant Depression Treatment sales are expected to flourish at a CAGR of 9.0%.
• By 2033, the market value of Treatment-Resistant Depression Treatment is expected to reach US$ 4.0 Billion

“The rising geriatric population is one of the factors that is anticipated to boost the growth of treatment-resistance depression treatment market, as the treatment-resistance depression treatment is high in this age group population,” remarks an FMI analyst.

Get a Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-15965

Competitive Landscape

Prominent players in the treatment-resistant depression treatment market are Janssen Global Services, LLC, AbbVie Inc., Sandoz International GmbH (Novartis AG), H. Lundbeck A/S, Par Pharmaceutical (Endo International plc), Otsuka Pharmaceutical Co., Ltd., and AstraZeneca, among others.

Recent Developments:

• In August 2022, Merck Sharp & Dohme LLC initiated Phase IIa clinical trial to evaluate the safety and efficacy of MK-1942 among treatment-resistant depression patients.
• In July 2022, Novartis Pharmaceuticals announced that it would initiate a Phase 2 clinical trial of MIJ821 (ketamine) for treatment-resistant depressive disorders in September 2022.
• In May 2022, COMPASS Pathways presented positive data for Phase IIb study of COMP360 psilocybin therapy for treatment-resistant depression treatment at the American Psychiatric Association annual meeting in New Orleans.
• In February 2022, Denova Biopharma secured U.S. FDA approval to initiate a Phase 2b clinical trial to analyze the efficacy and safety of DB104 (liafensine) in patients with treatment-resistant mood disorder.

Key Segments Covered in the Treatment-Resistant Depression Treatment Industry Analysis

Treatment-Resistant Depression Treatment Market by Drug Type:

• NMDA
• Antidepressants
• Antipsychotics
• Others

Treatment-Resistant Depression Treatment Market by Distribution Channel:

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Treatment-Resistant Depression Treatment Market by Region:

• North America
• Latin America
• Europe
• South Asia & Pacific
• East Asia
• Middle East & Africa

Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-15965

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs